XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.22.2

Certain Balance Sheet Accounts | 6 Months Ended
--- | ---
Jun. 30, 2022
Certain Balance Sheet Accounts |
Certain Balance Sheet Accounts | Note 5—Certain Balance Sheet Accounts OMIDRIA Contract Royalty Asset OMIDRIA contract royalty asset consists of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
​ | ​ | 2022 |  | 2021
​ | ​ | (In thousands)
Short-term contract royalty asset | ​ | $ | 43,794 | ​ | $ | 44,319
Long-term contract royalty asset | ​ | ​ | 126,812 | ​ | ​ | 140,251
Total OMIDRIA contract royalty asset | ​ | $ | 170,606 | ​ | $ | 184,570
​ ​ Receivables, net Receivables, net consists of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, | ​ | December 31,
​ |  | 2022 |  | 2021
​ | ​ | (In thousands)
Royalty and trade receivables, net | ​ | $ | 13,669 | ​ | $ | 36,505
Sublease and other receivables | ​ |  | 810 | ​ |  | 1,650
Total receivables, net | ​ | $ | 14,479 | ​ | $ | 38,155
​ Trade receivables are net of product return and chargeback allowances. Product returns and chargeback allowances were $2.0 million as of December 31, 2021. Property and Equipment, Net Property and equipment, net consists of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | December 31,
​ | ​ | 2022 | ​ | 2021
​ | ​ | (In thousands)
Finance leases | ​ | $ | 6,537 | ​ | $ | 5,979
Laboratory equipment | ​ |  | 3,123 | ​ |  | 3,091
Computer equipment | ​ |  | 1,076 | ​ |  | 1,069
Office equipment and furniture | ​ |  | 625 | ​ |  | 625
Total cost | ​ |  | 11,361 | ​ |  | 10,764
Less accumulated depreciation and amortization | ​ |  | (9,440) | ​ |  | (9,033)
Total property and equipment, net | ​ | $ | 1,921 | ​ | $ | 1,731
​ For the three months ended June 30, 2022 and 2021, depreciation and amortization expense was $0.2 million and $0.4 million, respectively. For the six months ended June 30, 2022 and 2021, depreciation and amortization expense was $0.5 million and $0.7 million, respectively. Accrued Expenses Accrued expenses consists of the following: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | June 30, |  | December 31,
​ | ​ | 2022 | ​ | 2021
​ | ​ | (In thousands)
Employee compensation | ​ | $ | 6,017 | ​ | $ | 3,706
Interest payable | ​ | ​ | 5,172 | ​ | ​ | 5,172
Clinical trials | ​ | ​ | 4,573 | ​ | ​ | 2,430
Consulting and professional fees | ​ | ​ | 3,179 | ​ | ​ | 7,455
Contract research and development | ​ |  | 2,889 | ​ |  | 3,916
Sales rebates, fees and discounts | ​ |  | 255 | ​ |  | 8,442
Other accrued expenses | ​ |  | 1,395 | ​ |  | 2,013
Total accrued expenses | ​ | $ | 23,480 | ​ | $ | 33,134
​

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration